IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease

Ann Rheum Dis. 2010 Feb;69(2):466-7. doi: 10.1136/ard.2009.108068.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antirheumatic Agents / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Male
  • Middle Aged
  • Receptors, Interleukin-1 / antagonists & inhibitors*
  • Still's Disease, Adult-Onset / drug therapy*
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Interleukin-1